Matrix metalloproteinase-9 in bronchiolitis obliterans syndrome after lung transplantation.

Activation of Tissue Remodeling Precedes Obliterative Bronchiolitis in Lung Transplant Recipients

Obliterative bronchiolitis (OB) and Bronchiolitis Obliterans Syndrome (BOS) are frequent complications in the lung transplant recipient, and are the leading cause of mortality after transplantation. The mechanisms responsible for OB remain elusive, but inflammatory and tissue remodeling responses are implicated. We hypothesized that alterations in markers of tissue remodeling in BALF of lung tr...

Syndrome after Lung Transplantation Chemoattractant in Bronchiolitis Obliterans The Presence of a Matrix-Derived Neutrophil

Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation.

OBJECTIVES Bronchiolitis obliterans is the greatest limitation to the long-term applicability of lung transplantation. Although alloimmune events are important, nonimmune events, such as gastroesophageal reflux, might contribute to lung injury and the development of bronchiolitis obliterans syndrome. METHODS We retrospectively studied the 396 patients who underwent lung transplantation at the...

TIMP-1 Deficiency Abrogates Obliterative Airway Disease after Heterotopic Tracheal Transplantation

Obliterative bronchiolitis (OB) is a major cause of allograft dysfunction after lung transplantation and is thought to result from immunologically mediated airway epithelial destruction and luminal fibrosis. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) have been implicated in the regulation of lung inflammation, airway epithelial repair and extracellular ...

Azithromycin and bronchiolitis obliterans syndrome after lung transplantation: is prevention better than cure?

A lthough lung transplantation is now accepted as an established therapy for selected patients with end-stage lung disease, long-term survival after lung transplantation remains limited by the development of bronchiolitis obliterans syndrome (BOS) in .50% of recipients [1]. BOS is the clinical manifestation of an inflammatory bronchiolitis associated with fibrotic remodelling of the small and m...